Free tool
Diagnostics stocks
We cover 6 companies grouped under the Diagnostics theme. The median market value in the group is $3.66B. Across the group, the median move over the past trading day is +3.03%. Price change over the past year runs from −27.7% to +134.1% across the middle 80 percent of the group, with a median of −9.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
6 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% | Nov 4, 2026 |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | −27.21% | Nov 4, 2026 |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% | Nov 5, 2026 |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% | Oct 27, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% | Oct 8, 2026 |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% | Oct 27, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.